Dr. Pluenneke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 North Green Hills Rd
Kansas City, MO 64154Phone+1 913-574-2520Fax+1 913-574-2612
Education & Training
- University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1993 - 1996
- University of Kansas School of MedicineResidency, Internal Medicine, 1990 - 1993
- University of Kansas School of MedicineClass of 1990
Certifications & Licensure
- MO State Medical License 1996 - 2026
- KS State Medical License 1991 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.Qamar J Khan, Colleen Bohnenkamp, Taylor E Monson, Milind A Phadnis, Lauren Clark
JCO Oncology Advances. 2025-01-01 - 25 citationsImpact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.Rachel Yoder, Bruce F Kimler, Joshua M Staley, Kelsey Schwensen, Yen Y Wang
NPJ Breast Cancer. 2022-07-11 - 49 citationsRandomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer...Priyanka Sharma, Bruce F. Kimler, Anne O'Dea, Lauren Nye, Yen Y. Wang
Clinical Cancer Research. 2021-02-15
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: